Venture Capital

Korro Bio Closes $91.5M Series A Financing To Advance The Next Frontier In Rna Therapeutics

by vcaonline.com posted 2weeks ago 17 views
Korro’s OPERA platform harnesses the body’s natural base editing machinery to program precise, single-base RNA edits to treat disease CAMBRIDGE, Mass., September 10, 2020-- Korro Bio, Inc. today announced a $91.5 million Series A financing to advance its novel platform for precise, single-base, RNA editing to modulate protein function for therapeutic applications. This financing enables Korro to advance its lead program to IND filing and establish a broad portfolio of innovative RNA editing therapies. The financing was led by Wu Capital with participation from current investors, Atlas Venture and New Enterprise Associates.

In this article